[Kynurenines and drug research]
Fanni Tóth1, Ferenc Fülöp2,3, István Szatmári2
1Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Interdiszciplináris Kiválósági Központ, Neurológiai Klinika,Szegedi TudományegyetemSzeged, Semmelweis u. 6., 6725.
Orvosi Hetilap
|March 17, 2020
Summary
Researchers synthesized novel kynurenic acid analogues to improve blood-brain barrier penetration for treating neurodegenerative diseases. These compounds showed effectiveness in preclinical models, offering a potential new therapeutic strategy.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Kynurenines, derived from tryptophan metabolism, are implicated in various physiological and pathological processes.
- Kynurenic acid, a key metabolite, exhibits neuroprotective properties but has poor blood-brain barrier (BBB) penetration.
- Imbalances in kynurenic acid levels are linked to neurodegenerative and neuropsychiatric disorders.
Purpose of the Study:
- To synthesize and pharmacologically evaluate novel kynurenic acid analogues.
- To enhance BBB penetration for potential therapeutic applications in neurological disorders.
Main Methods:
- Synthesis of new chemical entities based on the kynurenic acid structure.
- Pharmacological testing of synthesized analogues in relevant animal models of nervous system disorders.
Main Results:
- The novel kynurenic acid analogues demonstrated improved BBB penetration characteristics.
- These analogues were effective in preclinical models of conditions such as migraine and Huntington's disease.
- The findings suggest these analogues could be viable therapeutic agents.
Conclusions:
- Novel kynurenic acid analogues offer a promising therapeutic avenue for neurodegenerative diseases.
- Enhanced BBB penetration is crucial for developing effective treatments targeting the central nervous system.
- Further research and development are warranted, with patent applications filed.
Keywords:
kinurénsavkynurenic acidneurodegenerative diseaseneurodegenerációs betegségneuroprotectionneuroprotekcióMore Related Videos
07:04A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
Published on: August 19, 2018
10.9K
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
13.1K
Related Concept Videos
01:28Biosynthesis of Nucleic Acids
827
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
827
01:29Drugs Affecting Neurotransmitter Synthesis
2.0K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:28Renal Drug Excretion: Tubular Secretion
669
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
669
01:31Transducer Mechanism: Nuclear Receptors
2.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.2K
01:14Drug Metabolism: Phase II Reactions
4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K